摘要:
The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.
摘要:
The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders.
摘要:
The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.
摘要:
The present invention is directed to salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by NOP, for example depression, anxiety, alcohol abuse, etc. The present invention is further directed to process(es) for the preparation of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and its corresponding salts.
摘要:
The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.
摘要:
The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.
摘要:
The present invention is directed to novel processes for the preparation of sulfamide derivatives, useful in the treatment of epilepsy and related disorders.